Quarterly report pursuant to Section 13 or 15(d)

Revenue (Details)

v3.24.1.1.u2
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Jul. 01, 2021
Dec. 31, 2024
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]        
Total revenue     $ 0 $ 475
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio        
Disaggregation of Revenue [Line Items]        
Other long-term debt     600  
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Forecast        
Disaggregation of Revenue [Line Items]        
Proceeds from divestiture of businesses   $ 1,000    
Product revenue, net        
Disaggregation of Revenue [Line Items]        
Total revenue     $ 0 $ 475
Millipred | Teva        
Disaggregation of Revenue [Line Items]        
Percent of net profit for installment payments 50.00%      
Installment payment $ 500